Patents by Inventor Wolfgang Glaesner

Wolfgang Glaesner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fgf-21 Fusion Proteins
    Publication number: 20070237768
    Abstract: The invention provides specific FGF-21 compounds fused to specific IgG4-Fc or HSA derivatives resulting in fusion proteins that are biologically active with an extended elimination half-life and a slower clearance. These FGF-21 compound fusion proteins and compositions are useful in treating type 2 diabetes, obesity, and metabolic syndrome.
    Type: Application
    Filed: May 2, 2005
    Publication date: October 11, 2007
    Applicant: ELI LILLY AND COMPANY
    Inventors: Wolfgang Glaesner, Rohn Millican, Yu Tian, Sheng-Hung Tschang
  • GLP-1 fusion proteins
    Patent number: 7271149
    Abstract: The present invention relates to glucagon-like-1 compounds fused to proteins that have the effect of extending the in vivo half-life of the peptides. These fusion proteins can be used to treat non-insulin dependent diabetes mellitus as well as a variety of other conditions.
    Type: Grant
    Filed: November 29, 2001
    Date of Patent: September 18, 2007
    Assignee: Eli Lilly and Company
    Inventors: Wolfgang Glaesner, Radmila Micanovic, Sheng-Hung Rainbow Tschang
  • GLP-1 FUSION PROTEINS
    Publication number: 20070161087
    Abstract: The present invention relates to glucagon-like-1 compounds fused to proteins that have the effect of extending the in vivo half-life of the peptides. These fusion proteins can be used to treat non-insulin dependent diabetes mellitus as well as a variety of other conditions.
    Type: Application
    Filed: January 11, 2007
    Publication date: July 12, 2007
    Inventors: Wolfgang Glaesner, Radmila Micanovic, Sheng-Hung Tschang
  • Muteins of fibroblast growth factor 21
    Publication number: 20070142278
    Abstract: The present invention relates to novel muteins of human fibroblast growth factor 21 with improved pharmaceutical properties. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for treating type 2 diabetes, obesity, metabolic syndrome, and in reducing the mortality and morbidity of critically ill patients.
    Type: Application
    Filed: December 1, 2004
    Publication date: June 21, 2007
    Inventors: John Beals, Christopher Frye, Wolfgang Glaesner, Shun Li, Radhakrishnan Rathnachalam, Jing Shang, Beth Strifler, Radmila Micanovic
  • Erythropoietic compounds
    Publication number: 20070100133
    Abstract: The present invention addresses the need for better pharmaceutical agents for teating anemias by providing polymer derivatized non-glycosylated erythropoietic compounds which show stability and bioactivity in vivo. The invention further provides methods for preparing these derivatived proteins which involves the use of a linkerless aldehyde modification process.
    Type: Application
    Filed: September 14, 2006
    Publication date: May 3, 2007
    Inventors: John Beals, Wolfgang Glaesner, Radmila Micanovic, Rohn Millican, Derrick Witcher
  • Amidated glucagon-like peptide-1
    Patent number: 7199217
    Abstract: The present invention encompasses a GLP-1 analog and compositions and formulations thereof useful for the treatment of hyperglycemia and other various diseases and conditions in mammals.
    Type: Grant
    Filed: November 30, 2001
    Date of Patent: April 3, 2007
    Assignee: Eli Lilly and Company
    Inventors: Richard Dennis DiMarchi, Rohn Lee Millican, Jr., Wolfgang Glaesner
  • Glp-1 analog fusion proteins
    Publication number: 20070036806
    Abstract: The invention provides specific GLP-1 analogs fused to specific IgG4-Fc derivatives. These fusion proteins have an increased half-life, decreased immunogenicity, and reduce effector activity. The fusion proteins are useful in treating diabetes, obesity, irritable bowel syndrome and other conditions that would be benefited by lowering plasma glucose, inhibiting gastric and/or intestinal motility and inhibiting gastric and/or intestinal emptying, or inhibiting food intake.
    Type: Application
    Filed: June 10, 2004
    Publication date: February 15, 2007
    Applicant: Eli Lilly and Company
    Inventors: Wolfgang Glaesner, Rohn Millican, Andrew Vick
  • Glucagon-like peptide-1 analogs
    Publication number: 20060263849
    Abstract: Disclosed are glucagon-like peptide-1 (GLP-1) compounds with modifications at one or more of the following positions: 11, 12, 16, 22, 23, 24, 25, 27, 30, 33, 34, 35, 36, or 37. Methods of treating a subject in need of GLP-1 receptor stimulation using these GLP-1 compounds are also disclosed.
    Type: Application
    Filed: May 18, 2006
    Publication date: November 23, 2006
    Inventors: Wolfgang Glaesner, Rohn Millican
  • Glucagon-like peptide-1 analogs
    Publication number: 20060252693
    Abstract: Disclosed are glucagon-like peptide-1 (GLP-1) compounds with modifications at one or more of the following positions: 7, 8, 12, 16, 18, 19, 20, 22, 25, 27, 30, 33, and 37. Methods of treating a subject in need of GLP-1 receptor stimulation using these GLP-1 compounds are also disclosed.
    Type: Application
    Filed: July 6, 2006
    Publication date: November 9, 2006
    Inventors: Wolfgang Glaesner, Rohn Millican, Lianshan Zhang
  • Glucagon-like peptide-1 analogs
    Patent number: 7101843
    Abstract: Disclosed are glucagon-like peptide-1 (GLP-1) compounds with modifications at one or more of the following positions: 7, 8, 12, 16, 18, 19, 20, 22, 25, 27, 30, 33, and 37. Methods of treating a subject in need of GLP-1 receptor stimulation using these GLP-1 compounds are also disclosed.
    Type: Grant
    Filed: August 14, 2002
    Date of Patent: September 5, 2006
    Assignee: Eli Lilly and Company
    Inventors: Wolfgang Glaesner, Rohn Lee Millican, Lianshan Zhang
  • Glucagon-like peptide-1 analogs
    Patent number: 7084243
    Abstract: Disclosed are glucagon-like peptide-1 (GLP-1) compounds with modifications at one or more of the following positions: 11, 12, 16, 22, 23, 24, 25, 27, 30, 33, 34, 35, 36, or 37. Methods of treating these GLP-1 compounds are also disclosed.
    Type: Grant
    Filed: June 1, 2001
    Date of Patent: August 1, 2006
    Assignee: Eli Lilly and Company
    Inventors: Wolfgang Glaesner, Rohn Lee Millican
  • Extended glucagon-like peptide-1 analogs
    Publication number: 20060014241
    Abstract: The invention encompasses GLP-1 peptides with modifications at various positions coupled with an extended C-terminus that provides increased stability.
    Type: Application
    Filed: January 3, 2003
    Publication date: January 19, 2006
    Inventors: Wolfgang Glaesner, Wayne Kohn, Rohn Millican, Lianshan Zhang
  • Glucagon-like peptide-1analogs
    Publication number: 20040198654
    Abstract: Disclosed are glucagon-like peptide-1 (GLP-1) compounds with modifications at one or more of the following positions: 7, 8, 12, 16, 18, 19, 20, 22, 25, 27, 30, 33, and 37. Methods of treating a subject in need of GLP-1 receptor stimulation using these GLP-1 compounds are also disclosed.
    Type: Application
    Filed: January 29, 2004
    Publication date: October 7, 2004
    Inventors: Wolfgang Glaesner, Rohn Lee Millican, Lianshan Zhang
  • Amidated glucagon-like peptide-1
    Publication number: 20040132647
    Abstract: The present invention encompasses a GLP-1 analog and compositions and formulations thereof useful for the treatment of hyperglycemia and other various diseases and conditions in mammals.
    Type: Application
    Filed: June 10, 2003
    Publication date: July 8, 2004
    Inventors: Richard Dennis DiMarchi, Rohn Lee Millican Jr, Wolfgang Glaesner
  • GLP-1 Fusion Proteins
    Publication number: 20040053370
    Abstract: The present invention relates to glucagon-like-1 compounds fused to proteins that have the effect of extending the in vivo half-life of the peptides. These fusion proteins can be used to treat non-insulin dependent diabetes mellitus as well as a variety of other conditions.
    Type: Application
    Filed: May 29, 2003
    Publication date: March 18, 2004
    Inventors: Wolfgang Glaesner, Radmila Micanovic, Sheng-Hung Rainbow Tschang
  • Glucagon-like peptide-1 analogs
    Publication number: 20030220243
    Abstract: Disclosed are glucagon-like peptide 1 (GLP-1) compounds with modifications at one or more of the following positions: 11, 12, 16, 22, 23, 24, 25, 27, 30, 33, 34, 35, 36, or 37. Methods of treating these GLP-1 compounds are also disclosed.
    Type: Application
    Filed: November 19, 2002
    Publication date: November 27, 2003
    Inventors: Wolfgang Glaesner, Rohn Lee Millican